FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,090 | -89.2% | 984 | -75.7% | 0.00% | – |
| Q2 2023 | $19,297 | +5.8% | 4,054 | +26.7% | 0.00% | – |
| Q1 2023 | $18,234 | -20.8% | 3,199 | +40.2% | 0.00% | -100.0% |
| Q4 2022 | $23,015 | -11.5% | 2,281 | +98.2% | 0.00% | 0.0% |
| Q3 2022 | $26,000 | -3.7% | 1,151 | +7.6% | 0.00% | 0.0% |
| Q2 2022 | $27,000 | -20.6% | 1,070 | +22.8% | 0.00% | 0.0% |
| Q1 2022 | $34,000 | 0.0% | 871 | +48.1% | 0.00% | 0.0% |
| Q4 2021 | $34,000 | -35.8% | 588 | -34.7% | 0.00% | -50.0% |
| Q3 2021 | $53,000 | -32.9% | 901 | -0.7% | 0.00% | -33.3% |
| Q2 2021 | $79,000 | +393.8% | 907 | +372.4% | 0.00% | +200.0% |
| Q1 2021 | $16,000 | -5.9% | 192 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $17,000 | +112.5% | 192 | -5.4% | 0.00% | – |
| Q3 2020 | $8,000 | +60.0% | 203 | +31.0% | 0.00% | – |
| Q2 2020 | $5,000 | +66.7% | 155 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | – | 155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |